Risk of fractures in subjects with antihypertensive medications: A nationwide claim study

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 62-67

  Choi, Hyung Jin ^a   Park, Chanmi ^b   Lee, Young Kyun ^c   Ha, Yong Chan ^d   Jang, Sunmee ^e   Shin, Chan Soo ^f  

^a Chungbuk National University Hospital   (South Korea)

^b National Evidence Based Healthcare Collaborating Agency   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Chung Ang University College of Medicine   (South Korea)

^e Gachon University   (South Korea)

^f Seoul National University   (South Korea)

Author keywords

Antihypertensives; Fracture; Pharmacoepidemiology

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; COMORBIDITY; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; FEMALE; FOLLOW UP; FRACTURE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEX RATIO; SPINE FRACTURE; VERY ELDERLY; CHEMICALLY INDUCED; COHORT ANALYSIS; FACTUAL DATABASE; FRACTURES, BONE; INSURANCE; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH KOREA; TRENDS;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84934278648     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.01.072     Document Type: Article

References (29)

1. K.L. Ong, B.M. Cheung, Y.B. Man, C.P. Lau, K.S. Lam, Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004, Hypertension 49 (2007) 69-75.
2. M.E. Tinetti, C. Kumar, The patient who falls: "it's always a trade-off", JAMA 303 (2010) 258-266.
3. D.A. Butt, M. Mamdani, P.C. Austin, K. Tu, T. Gomes, R.H. Glazier, The risk of falls on initiation of antihypertensive drugs in the elderly, Osteoporos. Int. 24 (2013) 2649-2657.
4. M.E. Tinetti, L. Han, D.S. Lee, G.J. McAvay, P. Peduzzi, C.P. Gross, et al., Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults, JAMA Inter. Med. 174 (2014) 588-595.
5. D.A. Butt, M. Mamdani, P.C. Austin, K. Tu, T. Gomes, R.H. Glazier, The risk of hip fracture after initiating antihypertensive drugs in the elderly, Arch. Intern. Med. 172 (2012) 1739-1744.
6. P.C. Souverein, T.P. Van Staa, A.C. Egberts, J.J. De la Rosette, C. Cooper, H.G. Leufkens, Use of alpha-blockers and the risk of hip/femur fractures, J. Intern. Med. 254 (2003) 548-554.
7. M.J. Bolland, R.W. Ames, A.M. Horne, B.J. Orr-Walker, G.D. Gamble, I.R. Reid, The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women, Osteoporos. Int. 18 (2007) 479-486.
8. J.A. Pasco, M.J. Henry, K.M. Sanders, M.A. Kotowicz, E. Seeman, G.C. Nicholson, Betaadrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study, J. Bone Miner. Res. 19 (2004) 19-24.
9. R. Wasnich, J. Davis, P. Ross, J. Vogel, Effect of thiazide on rates of bonemineral loss: a longitudinal study, BMJ 301 (1990) 1303-1305.
10. R.G. Schlienger, M.E. Kraenzlin, S.S. Jick, C.R. Meier, Use of beta-blockers and risk of fractures, JAMA 292 (2004) 1326-1332.
11. L. Rejnmark, P. Vestergaard, L. Mosekilde, Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study, J. Hypertens. 24 (2006) 581-589.
12. H.J. Song, et al., Beta1 selectivity of beta-blockers and reduced risk of fractures in elderly hypertension patients, Bone 51 (2012) 1008-1015.
13. D.H. Solomon, H. Mogun, K. Garneau, M.A. Fischer, Risk of fractures in older adults using antihypertensive medications, J. Bone Miner. Res. 26 (2011) 1561-1567.
14. I.R. Reid, et al., beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures, J. Bone Miner. Res. 20 (2005) 613-618.
15. M. Wiens, M. Etminan, S.S. Gill, B. Takkouche, Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies, J. Intern. Med. 260 (2006) 350-362.
16. S. Kwon, Payment system reform for health care providers in Korea, Health Policy Plan. 18 (2003) 84-92.
17. H.J. Choi, et al., Burden of osteoporosis in adults in Korea: a national health insurance database study, J. Bone Miner. Metab. 30 (2012) 54-58.
18. C. Park, Y.C. Ha, S. Jang, H.K. Yoon, Y.K. Lee, The incidence and residual lifetime risk of osteoporosis-related fractures in Korea, J. Bone Miner. Metab. 29 (2011) 744-751.
19. R.A. Deyo, D.C. Cherkin, M.A. Ciol, Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases, J. Clin. Epidemiol. 45 (1992) 613-619.
20. R. Sikka, F. Xia, R.E. Aubert, Estimating medication persistency using administrative claims data, Am. J. Manage Care 11 (2005) 449-457.
21. E. Chrischilles, L. Rubenstein, J. Chao, K.J. Kreder, D. Gilden, H. Shah, Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study, Clin. Ther. 23 (2001) 727-743.
22. C. Feldstein, A.B. Weder, Orthostatic hypotension: a common, serious and underrecognized problem in hospitalized patients, J. Am. Soc. Hypertens. 6 (2012) 27-39.
23. H. Shimizu, et al., Angiotensin II accelerates osteoporosis by activating osteoclasts, FASEB J. 22 (2008) 2465-2475.
24. B.O. Donmez, et al., Effect of angiotensin II type 1 receptor blocker on osteoporotic rat femurs, Pharmacol. Rep. 64 (2012) 878-888.
25. T. Kwok, et al., Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men? Osteoporos. Int. 23 (2012) 2159-2167.
26. U.M. Steckelings, E. Kaschina, T. Unger, The AT2 receptor-a matter of love and hate, Peptides 26 (2005) 1401-1409.
27. T. Unger, M. Stoppelhaar, Rationale for double renin-angiotensin-aldosterone system blockade, Am. J. Cardiol. 100 (2007) 25J-31J.
28. S. Park, et al., Major role for ACE-independent intrarenal ANG II formation in type II diabetes, Am. J. Physiol. Renal Physiol. 298 (2010) F37-F48.
29. G. Karsenty, Convergence between bone and energy homeostases: leptin regulation of bone mass, Cell Metab. 4 (2006) 341-348.